Replies to post #175774 on Biotech Values

[jq1234]

>> I have to agree with the GILD camp that in 1A, naive, non-chirotic patients, GILD does have a real advantage.

Not if it is priced 20-30% higher if you ask me or majority payers.

[DewDiligence]

...in GT1a, naive, non-cirrhotic patients, GILD does have a real advantage.

Maybe. GILD hasn’t yet disclosed the GT1a and GT1b subgroup data from any of the ‘ION’ studies (#msg-96696670).